A Phase 1 interventional study of Psilocybin with facilitated counseling in Opioid Use Disorder, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University of Wisconsin, Madison · Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Opioid-Related Disorders by University of Wisconsin, Madison — 4 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · University of Wisconsin, Madison.
Among the 16 studies in Opioid-Related Disorders by University of Wisconsin, Madison, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 1, and was the 7th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 16 studies in Opioid-Related Disorders by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Women only
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 97 across the 14 interventional studies, 23,924 across the 2 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
3 of the studies in Opioid-Related Disorders by University of Wisconsin, Madison that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04161066University of Wisconsin, MadisonAdjunctive Effects of Psilocybin and a Formulation of Buprenorphine | 2026-12 |
| NCT06527599University of Wisconsin, MadisonScreening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention | 2026-12 |
| NCT07649278University of Wisconsin, MadisonThe ENHANCE Project Toolkit | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Opioid-Related Disorders by University of Wisconsin, Madison, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation.
Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy.
Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy.
Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.
The primary objective of this clinical trial is to determine the safety of psilocybin in adult patients with opioid use disorder concurrently taking buprenorphine-naloxone.
Eligible participants will be adults with active opioid use disorder (OUD) who are willing to begin and maintain a daily dose of buprenorphine-naloxone throughout study participation. Initiation, stabilization, and maintenance of buprenorphine-naloxone will be overseen by a qualified study medical provider. After psychological screening and at least 6 hours of preparatory counseling and preparation for the psilocybin dosing, set, and setting, each participant will ingest 1 oral dose of psilocybin. All dosing sessions will be attended by 2 specially trained facilitators, in a dedicated Clinical Research Facility. After eight hours of observation in the dosing room, the participant will be kept overnight in the hospital Clinical Research Unit, and complete an integration session with a psychologist before discharge to home. Approximately 4 weeks after the first dose, the participant will receive a second oral dose of psilocybin, with the same length of observation.
Participants who have been administered the first dose but decline to receive the second dose will remain evaluable. At study termination, their active study participation will end, but completion of the 28 day post-dose follow up will be requested.
The primary endpoint is the assessment of the safety of concurrent administration of a buprenorphine-naloxone formulation and psilocybin as determined by physiological measures (ECG, respiratory rate, blood pressure, body temperature, and blood oxygen saturation) and validated clinical and self-report measures (Clinical Opiate Withdrawal Scale (COWS), Opioid Craving Scale (OCS), Timeline Follow-Back (TLFB)).
If you are interested in participating in this study, please fill out a brief 1-minute survey at the link in the "More Information" section at the bottom of this record.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current opioid misuse, with misuse occurring on at least 10 of the last 30 days (at least 5 of last 30 days if already on buprenorphine/naloxene. See exclusion #1). Misuse will be defined as either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
Drug: Psilocybin with facilitated counseling
open-label pilot study
Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose
In participants with OUD, the safety of this intervention will be assessed by characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine regimen.
Time frame: approximately Week 1
Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose
In participants with OUD, the safety of this intervention will be assessed by characterizing adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone regimen.
Time frame: approximately Week 5
Mean Change in Symptoms of Opioid Withdrawal Measured by COWS Instrument
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause signs and symptoms of opioid withdrawal. This will be measured by the Clinical Opiate Withdrawal Scale (COWS) instrument, an 11-item scale administered by the clinician where total score of: 5- 12 = mild withdrawal; 13-24 = moderate withdrawal; 25-36 = moderately severe withdrawal; and more than 36 = severe withdrawal. Administered before the dose and again 8 hours after the dose.
Time frame: up to 5 weeks
Mean Change in Peripheral Capillary Oxygen
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause opioid intoxication. Opioid intoxication will be determined by drops peripheral capillary oxygen saturation (SpO2) before and after dosing.
Time frame: up to 5 weeks
Mean Change in ECG
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause a clinically significant increase in the QTc interval. The QTc interval will be measured by electrocardiogram (ECG) before and after dosing. If a QTc(F), calculated by the CardioCard system exceeds 470msec, a study physician will be contacted immediately for further monitoring and treatment recommendations.
Time frame: up to 5 weeks
Change in Opioid Craving Scale (OCS) from baseline through end of study
To evaluate the effect of psilocybin treatment on the effectiveness of buprenorphine-naloxone maintenance therapy. The hypothesis is that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause an increase in opioid craving, as measured by the OCS at baseline, week 1, week 5, and week 9. The OCS is a 3-item visual analog scale to measure the frequency and intensity of opioid craving. Total score ranges from 0-30 where the higher the number, the higher the craving.
Time frame: Baseline, Week 1, Week 5, and Week 9
Mean Number of Days of Participant Opioid Use via Time Line Follow Back (TLFB)
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not be associated with an increase in self-reported illicit opioid use. This will be measured by Time Line Follow-Back calendar method for up to the 28 days following the last dosing session. Participants will be asked to recall the previous 28 days of substance use at the first in-person visit.
Time frame: up to 9 weeks
Plan to share: No — No individual participant data sharing is planned
Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 71 months is above that.
Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →